Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Horrigan

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|May 14, 2017
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple MyelomaIoanna Savvidou, Tiffany Khong, Andrew Cuddihy, et al.
Journal of Virology|November 6, 2025
Replication-driven HBV cccDNA loss in chimeric mice with humanized liversBai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, et al.
Viruses|October 27, 2022
Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse ModelCheryl A Stoddart, Francesca Curreli, Stephen Horrigan, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2025
HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA eliminationBai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, et al.
BMC Biotechnology|July 26, 2018
The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in ratsPaul R Pentel, Michael D Raleigh, Mark G LeSage, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Replication-driven HBV cccDNA loss in chimeric mice with humanized liversBai-Hua Zhang, Yuanping Zhou, Ben Tempel, et al.
Plos One|July 30, 2021
Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodiesMichael D Raleigh, Nicola Beltraminelli, Stephanie Fallot, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|May 14, 2017
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple MyelomaIoanna Savvidou, Tiffany Khong, Andrew Cuddihy, et al.
Journal of Virology|November 6, 2025
Replication-driven HBV cccDNA loss in chimeric mice with humanized liversBai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, et al.
Viruses|October 27, 2022
Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse ModelCheryl A Stoddart, Francesca Curreli, Stephen Horrigan, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2025
HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA eliminationBai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, et al.
BMC Biotechnology|July 26, 2018
The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in ratsPaul R Pentel, Michael D Raleigh, Mark G LeSage, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Replication-driven HBV cccDNA loss in chimeric mice with humanized liversBai-Hua Zhang, Yuanping Zhou, Ben Tempel, et al.
Plos One|July 30, 2021
Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodiesMichael D Raleigh, Nicola Beltraminelli, Stephanie Fallot, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 1